Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Author:

Dummer Reinhard1,Hauschild Axel1,Santinami Mario1,Atkinson Victoria1,Mandalà Mario1,Kirkwood John M.1,Chiarion Sileni Vanna1,Larkin James1,Nyakas Marta1,Dutriaux Caroline1,Haydon Andrew1,Robert Caroline1,Mortier Laurent1,Schachter Jacob1,Lesimple Thierry1,Plummer Ruth1,Dasgupta Kohinoor1,Gasal Eduard1,Tan Monique1,Long Georgina V.1,Schadendorf Dirk1ORCID

Affiliation:

1. From University Hospital Zurich Skin Cancer Center, Zurich, Switzerland (R.D.); University Hospital Schleswig-Holstein, Kiel (A. Hauschild), University Hospital Essen, Essen (D.S.), and German Cancer Consortium, Heidelberg (D.S.) — all in Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute–IRCCS, Padua (V.C.S.) — all in Italy; Princess Alexandra Hospital, Gallipoli...

Funder

Novartis Pharmaceuticals Corporation

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3